木瓜直播

Roy Herbst, MD, PhD, leads a discussion on ADCs targeting TROP2, HER2, and HER3

Roy Herbst, MD, PhD, leads a discussion on current and emerging treatments available

Roy Herbst, MD, PhD, leads a discussion on the newest targeted and immunotherapies

Roy Herbst, MD, PhD, leads a discussion on new data coming down the pike